NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment [Video]

Dr. Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), joined Steve Darling from Proactive to discuss the company’s innovative approach to broad-spectrum antiviral therapies. At the forefront of their efforts is a cutting-edge treatment designed to combat a wide range of viruses, including Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMP), offering hope for more effective solutions to viral outbreaks.

Dr. Diwan explained that the treatment uses a novel mechanism, mimicking cellular receptors targeted by viruses to infect human cells, effectively neutralizing them with high potency. “If we have a battery of these [drugs] already available, then you don’t have a pandemic. You can beat it before it starts,” he said, underscoring the transformative potential of proactive antiviral therapies.

The company is preparing for a pivotal clinical trial focused on Severe Acute Respiratory Infections (SARIs). This trial will evaluate the therapy’s ability to target multiple viral families, highlighting its potential as a versatile tool for addressing respiratory and …